Human papillomavirus vaccine recombinant monovalent - Japan Vaccine/MedImmune

Drug Profile

Human papillomavirus vaccine recombinant monovalent - Japan Vaccine/MedImmune

Alternative Names: HPV 11 vaccine - Japan Vaccine/MedImmune; Human papillomavirus type 11 L1 virus-like particle vaccine - Japan Vaccine/MedImmune; Human papillomavirus type 11 L1 VLP vaccine - Japan Vaccine/MedImmune; MEDI 501

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Human papillomavirus infections

Most Recent Events

  • 29 Sep 2004 Discontinued - Phase-I for Human papillomavirus infections in USA (unspecified route)
  • 27 Aug 2003 No development reported - Phase-I for Human papillomavirus infections in USA (unspecified route)
  • 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top